- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Moffitt Cancer Center | Strategic Alliance Partners
Moffitt is dedicated to one lifesaving mission: to contribute to the prevention and cure of cancer. The Tampa-based facility is one of only 53 National Cancer Institute-designated Comprehensive Cancer Centers, a distinction that recognizes Moffitt’s scientific excellence, multidisciplinary research, and robust training and education. Moffitt’s expert nursing staff is recognized by the American Nurses Credentialing Center with Magnet® status, its highest distinction. With more than 7,800 team members, Moffitt has an economic impact in the state of $2.4 billion. For more information, call 1-888-MOFFITT (1-888-663-3488), visit MOFFITT.org, and follow the momentum on Facebook, Twitter, Instagram and YouTube.
Latest from Moffitt Cancer Center
Dr. Shain Discusses Novel Agents in Multiple Myeloma
August 31, 2018
Video
Kenneth H. Shain, MD, PhD, assistant member, Moffitt Cancer Center, discusses novel agents in multiple myeloma.
Dr. Kuykendall on the Impact of Ruxolitinib in Myeloproliferative Neoplasms
August 31, 2018
Video
Andrew T. Kuykendall, MD, assistant member, Moffitt Cancer Center, discusses the impact of ruxolitinib (Jakafi) in myeloproliferative neoplasms (MPNs).
Dr. Bello on Biomarkers in Follicular Lymphoma
August 31, 2018
Video
Celeste Bello, MD, hematologist/oncologist, Moffitt Cancer Center, discusses investigational biomarkers in follicular lymphoma.
Dr. Soliman on Investigational Combination Therapies in Patients With Breast Cancer
April 30, 2018
Video
Hatem Soliman, MD, medical oncologist, The Center for Women’s Oncology, Moffitt Cancer Center, discusses the use of combination therapies in the treatment of patients with breast cancer.
Expert Highlights Incorporation of Neoadjuvant Endocrine Therapy Into ER+ Breast Cancer
April 25, 2018
Article
Hung T. Khong, MD, discusses the benefits of neoadjuvant endocrine therapy and addresses the use of adjuvant endocrine therapy in ER-positive breast cancer.
Immunotherapy's Role in TNBC May Be in Combination
April 24, 2018
Article
Hatem Soliman, MD, discusses the potential role of immunotherapy in triple-negative breast cancer.
CAR T-Cell Therapy Starts to Enter MCL Space
April 23, 2018
Article
Frederick L. Locke, MD, discusses the ongoing ZUMA-2 trial investigating axi-cel for patients with mantle cell lymphoma.
Dr. Khong on the Benefit of Neoadjuvant Endocrine Therapy in ER+ Breast Cancers
March 30, 2018
Video
Hung T. Khong, MD, medical oncologist, Moffitt Cancer Center, discusses the use of neoadjuvant endocrine therapy.
Dr. Han on the Differences Between CDK 4/6 Inhibitors in ER+ Breast Cancer
March 30, 2018
Video
Heather S. Han, MD, research director, medical oncologist, Department of Breast Oncology, Moffitt Cancer Center, discusses the differences between CDK 4/6 inhibitors, and their efficacy as both single- and combination agents.
Strosberg Discusses Lutathera Approval, Remaining Challenges in NETs
March 01, 2018
Article
Jonathan R. Strosberg, MD, discusses ongoing advances and challenges in the treatment of patients with NETs.
Dr. Strosberg on Radiolabeled Somatostatin Analogs in GEP-NETs
February 12, 2018
Video
Jonathan R. Strosberg, MD, associate professor, Moffitt Cancer Center, discusses the development of radiolabeled somatostatin analogs in the treatment of patients with gastroenteropancreatic neuroendocrine tumors (GEP-NETs).
Locke Highlights Axi-Cel/Atezolizumab Data in DLBCL
February 01, 2018
Article
Frederick L. Locke, MD, discusses the initial data for axicabtagene ciloleucel (axi-cel; Yescarta) plus atezolizumab (Tecentriq) in diffuse large B-cell lymphoma, and reflected on the long-term survival data from the ZUMA-1 trial.
Dr. Strosberg on FDA Approval of Lutathera for GEP-NETs
January 26, 2018
Video
Jonathan Strosberg, MD, associate professor, Moffitt Cancer Center, discusses the FDA approval of Lutathera (177Lutetium DOTA-octreotate) as a treatment for patients with gastroenteropancreatic neuroendocrine tumors (GEP-NETs).
Dr. Shah on Toxicites Associated With CAR T-Cell Therapy
November 10, 2017
Video
Bijal D. Shah, MD, medical oncologist, Moffitt Cancer Center, comments on the toxicities associated with using chimeric antigen receptor (CAR) T-cell therapy in patients with leukemia.
Dr. Shah Discusses P53-Mutated Mantle Cell Lymphoma
October 24, 2017
Video
Bijal D. Shah, MD, medical oncologist, Moffitt Cancer Center, discusses treatment for patients with p53-mutated mantle cell lymphoma (MCL).
Dr. Chavez on Combination of Ibrutinib Plus Ublituximab in CLL
September 07, 2017
Video
Julio Chavez, MD, of the Department of Malignant Hematology at Moffitt Cancer Center, discusses the potential with the combination of ibrutinib (Imbruvica) and ublituximab (TGR-1101) in patients with chronic lymphocytic leukemia (CLL).
Dr. Shah on Excitement With Venetoclax in Patients With MCL
August 22, 2017
Video
Bijal D. Shah, MD, medical oncology, Moffitt Cancer Center, discusses the potential with venetoclax (Venclexta) in patients with mantle cell lymphoma (MCL).
Dr. Chavez Shares His Advice for Treating Patients With CLL
August 16, 2017
Video
Julio Chavez, MD, of the Department of Malignant Hematology at Moffitt Cancer Center, shares his advice for oncologists treating patients with chronic lymphocytic leukemia.
Dr. Chavez Discusses Ibrutinib Plus Venetoclax in CLL
August 14, 2017
Video
Julio Chavez, MD, of the Department of Malignant Hematology at Moffitt Cancer Center, discusses ibrutinib (Imbruvica) plus venetoclax (Venclexta) in chronic lymphocytic leukemia.
Dr. Shah on Options for Ibrutinib-Intolerant Patients With MCL
August 11, 2017
Video
Bijal D. Shah, MD, medical oncology, Moffitt Cancer Center, discusses a therapeutic option on the horizon for patients with mantle cell lymphoma (MCL) who are intolerant to ibrutinib (Imbruvica).